

PHARMACEUTICALS & BIOLOGICS

FANC: Potentiating Melphalan in Multiple Myeloma by Targeting the Fanconi Anemia/BRCA Resistance Pathway	03B097
VEGF/PDGF: Orally Bioavailable Small Molecule that Binds VEGF or PDGF for the Treatment of Cancer or Age-Related Macular Degeneration	03B114
RhoB: Variants for the Suppression of Malignancy	04B102
STAT3: Enhancing Immune Response to Tumor Cells	04B112
MRP1: Compounds for Treating Multidrug Resistance	04MA001
Raf/Mek/P-Erk: Inhibition of the Raf-1/Mek-1/Erk1/2 Pathway by the Beta-2-Adrenergic Receptor Agonist Pirbuterol	05B072
Src, Abl: Dasatinib on Drug-Eluting Stents for the Prevention and Treatment of Restenosis and Stenosis	05B111N
Rb/Raf: Orally active disruptors of the Rb/Raf-1 binding interaction	05B126
Shp2: Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors	06A038
BCR-ABL: Vorinostat co-treatment enhances dasatanib efficacy in CML	06B078N
Rho Kinase: Inhibitors as Novel Anti-Cancer Agents	06B134
Glut-1: Glucose Transporter Inhibitor Antibodies	07B083
SHIP: Inhibitors for Treating Graft vs. Host Disease and Transplant Rejection	08MB010
Topoisomerase II: Inhibitors of Nuclear Export of Topoisomerase II Alpha	08MB014
Aurora: Aurora A Kinase Inhibitors	09MA037
pH: Inhibition of Metastasis with Systemic Non-volatile Buffers	09MB048
Mcl-1: Asymmetrical Marinopyrroles as Anti-Cancer Agents	10MA018N
LPAAT: Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer	10MA019N
FT/GGT: Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor	10MB048
Topoisomerase II: Inhibitor Enhancer in Multiple Myeloma	10MB078
Proteasome: Non-covalent and Reversible Proteasome Inhibitors with an Oxadiazole-isopropylamide Core	10MB083
SHP2: Novel Small Molecule Oxindole Tyrosine Phosphatase Inhibitor	12MA024N
HDAC6: Novel Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group	12MA030
Mcl-1/Bcl-xL: Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents	12MA035N
CDC25C/PP2A/Lenalidomide: Conjugate Therapeutic with CpG, siRNAs, and Lenalidomide to Treat non-del(5q) MDS	12MB075N
IRE-1: Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-cell Cancer	12MB089
STAT3: STAT3 Dimerization Inhibitors	12MB098
Anti-infectives: Symmetrical Synthetic Marinopyrroles as anti-MRSA Therapeutics	12MB110
BRD4 JAK2: Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	14MB069
TAG72-CD3: Bispecific Antibody for Targeted Cancer Immunotherapy	14MB072
WEE1: Small molecule WEE1 inhibitor to treat cancer that inhibits WEE1 phosphorylation of H2B but not Cdc2	14MB092N
Ras: Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras	15MA011

FOR ADDITIONAL INFORMATION CONTACT

Haskell Adler PhD MBA
 Licensing
haskell.adler@moffitt.org
 (813) 745-6596

Latanya Scott PhD
 Industry Alliances
latanya.scott@moffitt.org
 (813) 745-6902

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

DIAGNOSTICS, VACCIINES,
 CELL THERAPIES, DEVICES,
 TOOLS, SOFTWARE

10.02.2017



PHARMACEUTICALS & BIOLOGICS (cont.)

Ras/Raf: Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction	15MA012
Aurora/JAK2: Dual Kinase Inhibitor targeting JAK2 and Aurora Kinase A for GVHD Prophylaxis	16MA005N
DOR: Delta opioid receptor ligand and anti-PD1 checkpoint inhibitor conjugates for immunotherapy of lung cancer	16MA029N
β-catenin/BCL-9: Small molecule inhibitors of the interaction of β-catenin and BCL-9	17MA014N
β-catenin/TCF: Small molecule inhibitors of the interaction of β-catenin and T-cell Factor	17MB040N

VACCINES & CELL THERAPIES

Vaccine Adjuvant: Flagellin-Based Adjuvant for Tumor Cell Vaccines that binds TLR5	04A028
Antibodies: MARCO for Enhanced Dendritic Cell Vaccine Efficacy	07MB004
Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination	11MA013
Cancer Vaccine: Use of a Variant Survivin Vaccine to Treat Myeloma	14MB098
TLR9: CAR-T cell constructs (chimeric antigen receptors) that Recognize TLR9	16MA025
AaPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain for Producing CAR-Ts	16MB049
AaPC: Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy	16MB050
TAG72: CAR-T cell constructs (chimeric antigen receptors) that Recognize TAG72	16MB057
IL-13Rα2: CAR-T cell constructs (chimeric antigen receptors) that Recognize IL-13Rα2	16MB069
CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy	17MA007
TIM3: CAR-T cell constructs (chimeric antigen receptors) that Recognize TIM3 to treat AML	17MA008
TILs: Rapid method for culture of TILs from core needle biopsies of solid tumors	17MA012N
CD33: CAR-T cell constructs (chimeric antigen receptors) that Recognize CD33 to Treat AML	17MA030N
CD123: CAR-T cell constructs (chimeric antigen receptors) that Recognize CD123 to Treat AML	17MA031N

DIAGNOSTICS

Protein Diagnostic: Characterization of Quantum Dots for Ovarian Cancer Detection	04A064
Protein Signature: Discriminating Common Adenocarcinomas	05A014
Genetic Signature: Metastatic Melanoma Stage Identification	06B073
Plasma Protein Biomarker: Diagnosis of Ovarian Cancer	06B098
Protein Biomarker: Predicting Response to Immunosuppression in MDS	07A056
Genetic Signature: Predicting Tumor Aggressiveness	07B108
Protein Biomarker: Diagnostic Marker for AML and MPD	07B113
Genetic Signature: Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues	08A016
Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence	08MA005
Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer	09MA014
Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP)	10MA009
Genetic Signature: Predicting High Grade Glioma Outcomes Using Senescence Associated Genes	10MA013
Molecular Imaging Probe: Non-invasive Detection of Breast Cancer in Lymph Nodes	10MA024
Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery	10MB069N

FOR ADDITIONAL INFORMATION CONTACT

PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA
 Licensing
haskell.adler@moffitt.org
 (813) 745-6596

Latanya Scott PhD
 Industry Alliances
latanya.scott@moffitt.org
 (813) 745-6902

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

DIAGNOSTICS, DEVICES TOOLS, SOFTWARE



DIAGNOSTICS (cont.)

Genetic Signature: CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking	11MA006
Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers	11MA014
Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma	11MA026N
Genetic Signature: Method of Detecting MDS Using hTERT Activity	11MB061N
Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes	11MB064
Genetic Signature: Predicting Response to Cancer Immunotherapy	11MB069
Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia	11MB072N
Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins	11MB087N
Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC	12MA023N
Genetic Signature: TGFβ response Signature in Non-Small Cell Lung Carcinoma	12MA029N
Genetic Signature: O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking	12MA034
Genetic Signature: Determining Prostate Cancer Recurrence Using Polymorphisms In Angiogenesis Genes	12MA045
Molecular Imaging Probe: Probes for Lung Cancer Intraoperative Guidance	12MA050N
Genetic Signature: E2F/Rb pathway signature to predict patient benefit from adjuvant chemo in NSCLC	12MA069
Molecular Imaging Probe: A Novel ¹⁸ F Scaffold for Preparing Targeted PET Imaging Probes	12MB104
Protein Diagnostic: Phosphorylated STAT3 Protein as a Biomarker of Graft Versus Host Disease	13MA002
Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma	13MA009
Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer	13MA036
Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma	13MB048N
Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis	13MB054
Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma	13MB055
Molecular Imaging: Novel PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging	13MB056N
miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs)	13MB078
miRNA Diagnostic: Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	13MB080
Genetic Signature: Predicting Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery	14MA008
Genetic Signature: Predicting Loco-regional Recurrence in Stage I-II Lung Cancer Following Surgery	14MA014N
Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy	14MA052N
Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients	15MA015

FOR ADDITIONAL INFORMATION CONTACT

DIAGNOSTICS, CELL THERAPIES PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA
Licensing
haskell.adler@moffitt.org
(813) 745-6596

Latanya Scott PhD
Industry Alliances
latanya.scott@moffitt.org
(813) 745-6902

Jarett Rieger Esq. MBA
Sr. Director, Innovation Office
jarett.rieger@moffitt.org
(813) 745-6828

DIAGNOSTICS DEVICES, TOOLS SOFTWARE



DIAGNOSTICS (cont.)

Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS	15MA021N
Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration	15MA031N
Diagnostic: 18F-FDG in Red Blood Cells as an Alternative to the MUGA Scan	15MB042N
Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression	15MB065
Genetic Signature: Diagnostic to Distinguish Lung Carcinoma from Metastatic Head & Neck Carcinoma	16MB040
Diagnostic: Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict Chemoradiation Response Using AQUA	16MB041
Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide	16MB042
Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent	16MB044
miRNA Diagnostic: Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	16MB066

DEVICES, TOOLS & SOFTWARE

Med Device: Objective Imaging Reference Standards	07A049
Med Device: Ventana Inline Dispenser Float Mechanism	09MB053
Med Device: Handheld Radioisotope Identification Device (RIID)	10MB054
Med Device: Muscle Stapler	10MB065N
Med Device: Pump-assisted High Flow Rate Isolated Limb Infusion for Regional Cancer Treatment	11MB017N
Med Device: Minimally Invasive Spinal Fusion Using a Transdiscal Screw System	11MA021
Med Device: Vascular Stent for Anastomosis	12MA054N
Med Device: Arterial Line Catheter Modification	12MA067
Med Device: Improved Enteral Feeding Tube and Retention Disc to Reduce Dislodgement, Infection and Complications	13MA001
Med Device: Improved Orogastric Tube Guide	13MA030
Med Device: Expandable Intervertebral Cage	14MB067N
Med Device: Improved Pigtail Drainage Catheter for Percutaneous Fluid Aspiration	15MA034
Med Device: Safety Catheter with Needle and Blood Exposure Prevention Systems	15MB064
Med Device: Novel Endotracheal Tube Intubating Stylet	16MA021
Med Device: Anesthesia Intra-oral Monitoring System (AIMS) (Replacement for the Nasal Cannula)	16MB046
Research Tool: Novel Electroporation Buffer Formulation for Enhanced Efficiency and Viability	05B141
Software: Method for Improved Detection of Lung Function and Management of Lung Cancer Radio Therapy	10MA037N
Software: Method for Improving the Accuracy of Charged Particle Beam Radiotherapy	12MB072
Software: Automated Technique for Generating BIRADS Scores from Mammograms	13MA025
Software: A Quantitative Framework to Identify Radiation Targets for Cancer Treatment that Synergize with Immunotherapy (Abscopal Effect)	14MA022
Software: Negative Information Storage Model for Genomic Data	15MA033

